Linked Life Data

17102612

Source:http://linkedlifedata.com/resource/pubmed/id/17102612

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20
pubmed:dateCreated
2006-11-19
pubmed:abstractText
The PI3 kinase pathway is among the most frequently activated signaling pathways in human cancer and represents an attractive target for small molecule inhibitor based therapies. The PI3Ks show considerable diversity however, and it remains unclear which kinases in this family should be targeted in cancer. We recently screened a panel of potent and structurally diverse drug-like molecules that target this enzyme family in glioma, a malignancy that shows frequent activation of PI3K signaling. Although PI3Kalpha was the major isoform driving malignant progression in glioma, blockade of PI3Kalpha was not sufficient to maximally inhibit glioma cells. A single agent that inhibited both PI3Kalpha and mTOR targeted two points in a pathway with multiple levels of feedback, and was essential for shutting down the proliferation of glioma cells. This result suggests a potentially effective strategy for cancer therapy based on dual inhibition of these two PI3K family members.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1551-4005
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2301-5
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Isoform specific inhibitors of PI3 kinase in glioma.
pubmed:affiliation
Department of Neurology, Pediatrics, Neurological Surgery, and Brain Tumor Research Center, Comprehensive Cancer Center, San Francisco, California 94143, USA.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural